Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: kaneda h. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
Establishing a new human lung squamous cell carcinoma cell line, OMUL-1, expressing insulin-like growth factor 1 receptor and programmed cell death ligand 1.
Nagamine H, Yashiro M, Mizutani M, Sugimoto A, Matsumoto Y, Tani Y, Kaneda H, Yamada K, Watanabe T, Asai K, Suzuki S, Kawaguchi T. Nagamine H, et al. Among authors: kaneda h. Thorac Cancer. 2024 Nov 17. doi: 10.1111/1759-7714.15488. Online ahead of print. Thorac Cancer. 2024. PMID: 39552203 Free article.
Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer.
Sugimoto A, Kaneda H, Yoshimoto N, Nagata K, Fujii T, Michimoto K, Ueno S, Kamimori T, Ishii Y, Sakagami M, Inokuchi H, Shibuya K, Mizutani M, Nagamine H, Nakahama K, Matsumoto Y, Tani Y, Sawa K, Kawaguchi T. Sugimoto A, et al. Among authors: kaneda h. Sci Rep. 2024 Aug 23;14(1):19596. doi: 10.1038/s41598-024-70214-y. Sci Rep. 2024. PMID: 39179598 Free PMC article.
Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.
Nagamine H, Yashiro M, Mizutani M, Sugimoto A, Matsumoto Y, Tani Y, Sawa K, Kaneda H, Yamada K, Watanabe T, Asai K, Suzuki S, Kawaguchi T. Nagamine H, et al. Among authors: kaneda h. PLoS One. 2024 Oct 4;19(10):e0297397. doi: 10.1371/journal.pone.0297397. eCollection 2024. PLoS One. 2024. PMID: 39365756 Free PMC article.
612 results